118 related articles for article (PubMed ID: 9288168)
1. Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.
Hamel P; Riendeau D; Brideau C; Chan CC; Desmarais S; Delorme D; Dubé D; Ducharme Y; Ethier D; Grimm E; Falgueyret JP; Guay J; Jones TR; Kwong E; McAuliffe M; McFarlane CS; Piechuta H; Roumi M; Tagari P; Young RN; Girard Y
J Med Chem; 1997 Aug; 40(18):2866-75. PubMed ID: 9288168
[TBL] [Abstract][Full Text] [Related]
2. Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.
Delorme D; Ducharme Y; Brideau C; Chan CC; Chauret N; Desmarais S; Dubé D; Falgueyret JP; Fortin R; Guay J; Hamel P; Jones TR; Lépine C; Li C; McAuliffe M; McFarlane CS; Nicoll-Griffith DA; Riendeau D; Yergey JA; Girard Y
J Med Chem; 1996 Sep; 39(20):3951-70. PubMed ID: 8831761
[TBL] [Abstract][Full Text] [Related]
3. Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid.
Hutchinson JH; Riendeau D; Brideau C; Chan C; Falgueyret JP; Guay J; Jones TR; Lépine C; Macdonald D; McFarlane CS
J Med Chem; 1994 Apr; 37(8):1153-64. PubMed ID: 8164257
[TBL] [Abstract][Full Text] [Related]
4. Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816.
Hutchinson JH; Riendeau D; Brideau C; Chan C; Delorme D; Denis D; Falgueyret JP; Fortin R; Guay J; Hamel P
J Med Chem; 1993 Sep; 36(19):2771-87. PubMed ID: 8410991
[TBL] [Abstract][Full Text] [Related]
5. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
[TBL] [Abstract][Full Text] [Related]
6. 5-Lipoxygenase inhibitors: synthesis and structure-activity relationships of a series of 1-aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones.
Bhatia PA; Brooks CD; Basha A; Ratajczyk JD; Gunn BP; Bouska JB; Lanni C; Young PR; Bell RL; Carter GW
J Med Chem; 1996 Sep; 39(20):3938-50. PubMed ID: 8831760
[TBL] [Abstract][Full Text] [Related]
7. Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.
Ducharme Y; Brideau C; Dubé D; Chan CC; Falgueyret JP; Gillard JW; Guay J; Hutchinson JH; McFarlane CS; Riendeau D
J Med Chem; 1994 Feb; 37(4):512-8. PubMed ID: 8120869
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
9. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.
Brideau C; Chan C; Charleson S; Denis D; Evans JF; Ford-Hutchinson AW; Fortin R; Gillard JW; Guay J; Guévremont D
Can J Physiol Pharmacol; 1992 Jun; 70(6):799-807. PubMed ID: 1330258
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: a novel 5-lipoxygenase inhibitor.
Shirumalla RK; Sharma P; Dastidar SG; Paliwal JK; Kakar S; Varshney B; Singh Saini G; Sattigeri V; Salman M; Ray A
Inflamm Res; 2008 Mar; 57(3):135-43. PubMed ID: 18369577
[TBL] [Abstract][Full Text] [Related]
12. A prodrug of a 2,6-disubstituted 4-(2-arylethenyl)phenol is a selective and orally active 5-lipoxygenase inhibitor.
Farina PR; Graham AG; Homon CA; Lazer ES; Hattox SE; Riska PS; Gundel RH; Wegner CD
J Pharmacol Exp Ther; 1993 May; 265(2):483-9. PubMed ID: 8388452
[TBL] [Abstract][Full Text] [Related]
13. Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
Adams JL; Garigipati RS; Sorenson M; Schmidt SJ; Brian WR; Newton JF; Tyrrell KA; Garver E; Yodis LA; Chabot-Fletcher M; Tzimas M; Webb EF; Breton JJ; Griswold DE
J Med Chem; 1996 Dec; 39(26):5035-46. PubMed ID: 8978834
[TBL] [Abstract][Full Text] [Related]
14. Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.
Hutchinson JH; Charleson S; Evans JF; Falgueyret JP; Hoogsteen K; Jones TR; Kargman S; Macdonald D; McFarlane CS; Nicholson DW
J Med Chem; 1995 Oct; 38(22):4538-47. PubMed ID: 7473582
[TBL] [Abstract][Full Text] [Related]
15. Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.
Kolasa T; Brooks CD; Rodriques KE; Summers JB; Dellaria JF; Hulkower KI; Bouska J; Bell RL; Carter GW
J Med Chem; 1997 Feb; 40(5):819-24. PubMed ID: 9057869
[TBL] [Abstract][Full Text] [Related]
16. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics.
Müller-Peddinghaus R; Kohlsdorfer C; Theisen-Popp P; Fruchtmann R; Perzborn E; Beckermann B; Bühner K; Ahr HJ; Mohrs KH
J Pharmacol Exp Ther; 1993 Oct; 267(1):51-7. PubMed ID: 8229782
[TBL] [Abstract][Full Text] [Related]
17. Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase.
Lau CK; Bélanger PC; Dufresne C; Scheigetz J; Therien M; Fitzsimmons B; Young RN; Ford-Hutchinson AW; Riendeau D; Denis D
J Med Chem; 1992 Apr; 35(7):1299-318. PubMed ID: 1313879
[TBL] [Abstract][Full Text] [Related]
18. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework.
Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Imai K; Inamura N; Asano M; Hatori C; Katayama A; Oku T; Tanaka H
J Med Chem; 1998 Feb; 41(4):564-78. PubMed ID: 9484506
[TBL] [Abstract][Full Text] [Related]
19. Quinolines as potent 5-lipoxygenase inhibitors: synthesis and biological profile of L-746,530.
Dubé D; Blouin M; Brideau C; Chan CC; Desmarais S; Ethier D; Falgueyret JP; Friesen RW; Girard M; Girard Y; Guay J; Riendeau D; Tagari P; Young RN
Bioorg Med Chem Lett; 1998 May; 8(10):1255-60. PubMed ID: 9871745
[TBL] [Abstract][Full Text] [Related]
20. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.
Gillard J; Ford-Hutchinson AW; Chan C; Charleson S; Denis D; Foster A; Fortin R; Leger S; McFarlane CS; Morton H
Can J Physiol Pharmacol; 1989 May; 67(5):456-64. PubMed ID: 2548691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
